OR33-5 Low Systemic Levels of Segesterone Acetate are Required to Inhibit Ovulation in Women

A one-year segesterone acetate (SA)/ethinyl estradiol (EE) contraceptive vaginal system (CVS; Annovera™) used to prevent pregnancy in women of reproductive age, was recently approved by the FDA (August 2018). Efficacy (Pearl Index of 2.98) and safety of the CVS were demonstrated in two phase 3, open...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Endocr Soc
Päätekijät: Archer, David, Sitruk-Ware, Regine, Mirkin, Sebastian, Brache, Vivian, Merkatz, Ruth, Kumar, Narender
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Endocrine Society 2019
Aiheet:
Reproductive Endocrinology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6554891/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR33-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia